NCT03061214 - Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Biotech Hunter

Enrollment

868

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

March 14, 2019

Study Completion Date

April 15, 2019

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide 0.5 mg

Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks

DRUG

Semaglutide 1.0 mg

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks

DRUG

Sitagliptin placebo

Sitagliptin placebo tablets taken once-daily for 30 weeks

DRUG

Sitagliptin

100 mg sitagliptin tablets taken once-daily for 30 weeks

DRUG

Semaglutide placebo 0.5 mg

Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks

DRUG

Semaglutide placebo 1.0 mg

Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks

Trial Locations (67)

112

Novo Nordisk Investigational Site, Taipei

114

Novo Nordisk Investigational Site, Taipei

333

Novo Nordisk Investigational Site, Taoyuan

1466

Novo Nordisk Investigational Site, Boksburg

1812

Novo Nordisk Investigational Site, Johannesburg

4091

Novo Nordisk Investigational Site, Durban

13620

Novo Nordisk Investigational Site, Seongnam-si, Gyeonggi-do

16247

Novo Nordisk Investigational Site, Suwon-si, Gyeonggi-do

16499

Novo Nordisk Investigational Site, Suwon

26426

Novo Nordisk Investigational Site, Wŏnju

35015

Novo Nordisk Investigational Site, Daejeon

49038

Novo Nordisk Investigational Site, Dnipro

79010

Novo Nordisk Investigational Site, Lviv

100034

Novo Nordisk Investigational Site, Beijing

100039

Novo Nordisk Investigational Site, Beijing

100044

Novo Nordisk Investigational Site, Beijing

100088

Novo Nordisk Investigational Site, Beijing

100730

Novo Nordisk Investigational Site, Beijing

101200

Novo Nordisk Investigational Site, Beijing

110004

Novo Nordisk Investigational Site, Shenyang

130021

Novo Nordisk Investigational Site, Changchun

130041

Novo Nordisk Investigational Site, Changchun

131000

Novo Nordisk Investigational Site, Yanji

161005

Novo Nordisk Investigational Site, Qiqihar

200040

Novo Nordisk Investigational Site, Shanghai

200072

Novo Nordisk Investigational Site, Shanghai

200240

Novo Nordisk Investigational Site, Shanghai

200336

Novo Nordisk Investigational Site, Shanghai

210011

Novo Nordisk Investigational Site, Nanjing

210029

Novo Nordisk Investigational Site, Nanjing

212001

Novo Nordisk Investigational Site, Zhenjiang

213003

Novo Nordisk Investigational Site, Changzhou

215006

Novo Nordisk Investigational Site, Suzhou

230001

Novo Nordisk Investigational Site, Hefei

230061

Novo Nordisk Investigational Site, Hefei

250013

Novo Nordisk Investigational Site, Jinan

266003

Novo Nordisk Investigational Site, Qingdao

300052

Novo Nordisk Investigational Site, Tianjin

330006

Novo Nordisk Investigational Site, Nanchang

350025

Novo Nordisk Investigational Site, Fuzhou

404000

Novo Nordisk Investigational Site, Chongqing

410013

Novo Nordisk Investigational Site, Changsha

423000

Novo Nordisk Investigational Site, Chenzhou

510080

Novo Nordisk Investigational Site, Guangzhou

510120

Novo Nordisk Investigational Site, Guangzhou

510515

Novo Nordisk Investigational Site, Guangzhou

519000

Novo Nordisk Investigational Site, Zhuhai

550004

Novo Nordisk Investigational Site, Guiyang

650101

Novo Nordisk Investigational Site, Kunming

710061

Novo Nordisk Investigational Site, Xi'an

750004

Novo Nordisk Investigational Site, Yinchuan

74935-530

Novo Nordisk Investigational Site, Aparecida de Goiânia

91350-250

Novo Nordisk Investigational Site, Porto Alegre

01228-200

Novo Nordisk Investigational Site, São Paulo

030001

Novo Nordisk Investigational Site, Taiyuan

Unknown

Novo Nordisk Investigational Site, Shatin, New Territories